Nonalcoholic Steatohepatitis (NASH) Market Worth US$ 20.0 Billion by 2025
Global Non-Alcoholic Steatohepatitis (NASH) market is expected to cross US$ 20.0 Billion by 2025 growing at a CAGR of more than 10.0% during given forecast period from 2016-2025.
Browse Full Report: http://www.marketresearchengine.com/reportdetails/non-alcoholic-steatohepatitis-nash-market
Nonalcoholic Steatohepatitis (NASH) is a disease which occurs in the people who are non alcoholic. The liver damage that is caused in patients is histologically indistinguishable from alcoholic hepatitis. The people suffering from NASH are having fats in the liver along with inflammation and damage. Most people suffering from NASH are not aware of the disease and people feel well. This is a severe form of syndrome and often leads to cirrhosis. People suffering from obesity, dyslipidemia, and glucose intolerance are more prone to NASH. Insulin resistance is found in most of the patients. Most of the patients are asymptomatic. In order to confirm the disease Biopsy is essential. The treatment is done by eliminating the risk factors. The majority of the people in the developed countries suffer from the disease, North America is presumed to be containing the majority of the people suffering from NASH. People suffering from NASH are recommended to go for weight reduction, take a balanced and healthy diet and have good physical activity.
The major driving factors of Nonalcoholic Steatohepatitis (NASH) market are as follows:
1. There is a great increase in the cycles of the clinical trials with increased success rates. Hence there are increased chances of getting a commercial approval by 2017.
The restraining factors of Nonalcoholic Steatohepatitis (NASH) market are as follows:
1. The unexplained and complex physiological structure.
2. Inefficient diagnostics technology which lengthen the commercialization of NASH therapeutics.
Download Free Sample Report: http://www.marketresearchengine.com/requestsample/non-alcoholic-steatohepatitis-nash-market
The Nonalcoholic Steatohepatitis market is segmented on the lines of its Therapeutics such as GFT505, Obeticholic Acid (INT-747) Simtuzumab and Liraglutide (Victoza)Vitamin EPioglitazonePlacebo. The Nonalcoholic Steatohepatitis market geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
This report provides:
1) An overview of the global market for Non alcoholic Steatohepatitis and related technologies.
2) Analyses of global market trends and projections of compound annual growth rates (CAGRs) through 2025.
3) Identifications of new market opportunities and targeted promotional plans for Non alcoholic steatohepatitis market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
The scope of the report includes a detailed study of global and regional markets for various types of Non alcoholic steatohepatitis with the reasons given for variations in the growth of the industry in certain regions. The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market.
Nonalcoholic Steatohepatitis market is segmented into therapeutic types and geography.
Obeticholic Acid (INT-747)
Simtuzumab and Liraglutide (Victoza)
Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.
Company Name: Market Research Engine
Contact Person: John Bay
Phone: +1-855-984-1862, +91-860-565-7204
Country: United States
Address: 3422 SW 15 Street, Suite #8942, Deerfield Beach, FL 33442, United States
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nonalcoholic Steatohepatitis (NASH) Market Worth US$ 20.0 Billion by 2025 here
News-ID: 393865 • Views: 284
More Releases from Market Research Engine (MRE)
Floating Production Systems Market is Expected to Cross US$ 40.0 Billion Globall …
Product type segment in the FPS market comprises FPSO, TLP, SPAR and FSO. FPSO is expected to be the most dominating product in terms of demand for FPS. Various companies such as Royal Dutch Shell Plc, ENI, Petrobras and Premier Oil are using FPSO to extract crude oil from offshore fields. FSO is similar to FPSO except production facility that can be carried out on FPSO. Multiple tasks can be
Energy Trading & Risk Management (ETRM) Market is Expected to Exceed US$ 1,351.5 …
“The market is largely driven by the key verticals such as power, natural gas, oil and products, natural gas liquids and coal”. The Global Energy Trading & Risk Management (ETRM) market penetration in Natural Gas & Oil Products is expected to be more than 55% by the end of 2015. The increased amount of trading in Oil & Products sector are expected to drive the Global ETRM market from
Liquid Nitrogen Market is Expected to Reach US$ 15.0 Billion Globally by 2022
Liquid Nitrogen, as a Fuel, is future of Green cars because it is very cheap compared to hydrogen and electric powered cars, which are seen as Zero Emission alternatives to Petrol and Diesel. Wherever low temperatures are needed there liquid nitrogen is used as a cryogen. It is used in cryosurgeries, cryotherapies, and cryopreservation to destroy decayed tissues and for removing warts, moles, skin tags, verrucae, and some skin cancers.
Cancer Immunotherapy Market is Expected to Reach US$ 145 Billion Globally by 202 …
The cancer immunotherapy market is segmented on the lines of its type, application, end user and regional. Based on type segmentation it covers immunomodulators, checkpoint inhibitors, cancer vaccines and monoclonal antibodies. Under application segmentation it covers melanoma, colorectal cancer, prostate cancer, head and neck cancer, breast cancer and lung cancer. Browse Full Report @: https://www.marketresearchengine.com/reportdetails/cancer-immunotherapy-market How Big is the Cancer Immunotherapy Market? The cancer immunotherapy market is expected to grow more than US$
More Releases for NASH
NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
Overview of NASH - Opportunity Analysis and Forecasts to 2026
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will
Leah Nash new photographer at Gruppe28
Gruppe28 is pleased to announce that Leah Nash joined its international network of high quality photographers. She will be presented exclusively and internationally by the photo agency Gruppe28 based in Hamburg, Germany. Leah Nash is an award winning, Portland-based photographer with a passion for documenting the everyday and the extreme, which she often finds are one and the same. Her work was published in distinguished magazines and newspapers including Mother